retatrutide and liver Fatty disease was alleviated by Lilly's 'triple-G' obesity drug Triple hormone receptor agonist retatrutide

The problem: Why GLP-1 skin behaves differently Many of these changes to the facial appearance stem not only from the loss of fat volume but also from emerging hypotheses about how GLP-1s affect skin integrity

126 , 014101 (2007) Berendsen, H

The GLP-1 drugs can have rare but serious side effects, the experts noted

The evaluating clinician determines whether this option is appropriate based on individual health factors

Design: Randomized, double-blind, placebo-controlled Phase 2 trial

Research Findings The clinical development program for retatrutide has produced some of the most impressive weight loss results ever documented in pharmacological obesity trials, generating significant excitement and positioning the compound as a potential paradigm-shifting therapy